Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.
The article says Alphabet’s inclusion in the Dow and Berkshire Hathaway’s increased holding drew attention, but focuses on Prestige Consumer Healthcare (PBH). It reports PBH closed a $1.045B acquisition of Breathe Right and other OTC brands on June 15, adding ~$200M annual revenue and ~$95M EBITDA, and notes net leverage ~4.0x at closing.
How this was made
The 30-second read
Why it matters
For PBH, the actionable content is the June 15 acquisition close, deal economics, and leverage at closing, plus management’s leverage target by FY2028.
Market read
PBH’s disclosed acquisition economics and leverage profile can drive near-term trading via credit/cash-flow expectations and execution risk, even if the article is largely promotional.
What to watch
Execution risk is underweighted—integration costs, promotional intensity needed to broaden use cases, and whether Breathe Right’s performance sustains the projected leverage path are the key swing factors.
Background
The piece frames Alphabet’s Dow inclusion and Berkshire’s portfolio move, then pivots to Prestige Consumer Healthcare’s acquisition-driven growth strategy.
Ticker impact
Prestige Consumer Healthcare says it closed its largest deal on June 15: a $1.045B purchase of Breathe Right and other OTC brands from Foundation Consumer Healthcare.
Likely supports a modest positive bias on deal execution expectations, but leverage (~4.0x) can cap upside if cash flow underperforms.
The article provides deal economics ($200M revenue, $95M EBITDA), timing (closed June 15), and leverage at closing (~4.0x) plus a stated leverage target by FY2028 (<3.0x). That combination is actionable for positioning, though it’s still framed as analysis rather than new market data.
Market effects
Highlights how OTC brand roll-ups can be repositioned toward GLP-1 side-effect demand, potentially influencing sentiment toward consumer healthcare M&A and category-brand strategies.
No clear regional market catalyst beyond Australia expansion via LaCorium Health.
Limited; the story is primarily North America OTC with a specific Australia footprint deepening.
Counterpoint
The GLP-1 angle may be overstated: side-effect demand could be cyclical with weight-loss drug adoption and patient adherence, while leverage raises downside if integration or cash flow disappoints.
Key entities
- companyPrestige Consumer Healthcare
OTC healthcare brand owner; closed a $1.045B acquisition of Breathe Right and other labels on June 15 and discussed leverage and integration outlook.
- brandBreathe Right
Nasal strip brand that became PBH’s single largest brand after the acquisition close.
- sellerFoundation Consumer Healthcare
Counterparty in the Breathe Right and other OTC labels transaction.
- companyLaCorium Health
Australia-based therapeutic skincare brand PBH agreed to acquire, deepening its existing Australia presence.
